N

Nouscom

HealthCancer ImmunotherapyB2B📍 Switzerland

Nouscom is a biotechnology company developing novel cancer immunotherapies. Their innovative approach aims to bring advanced treatments closer to clinical trials. This funding will support the advancement of their pipeline.

Total raised
Undisclosed
tracked to date
Latest round
€120 million
Oct 19, 2026

Is this your company?

Claim this profile to get matched with investors who fund Health startups in Switzerland.

Claim this profile →

🏆 Featured in Datapile’s Q4 2026 Switzerland Funding Report

Read the Q4 2026 Switzerland report →
Add this badge to your site
<a href="https://datapile.co/reports/q4-2026-switzerland-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q4 2026 Switzerland Funding Report</a>

Funding history

  1. 1
    €120 millionOct 19, 2026
    Announcement ↗

Nouscom in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile